SCHEMBL14745433

SCHEMBL14745433

COC(=O)c1cc2c(n(Cc3ccc(OC)cc3OC)c1=O)-c1ccc(Cl)cc1OCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ROCK2 O75116 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
ALPL P05186 1/20 0.37
THRB P10828 1/20 0.37
TSHR P16473 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CCR4 P51679 1/20 0.36
P2RX7 Q99572 1/20 0.36
MAOB P27338 1/20 0.36
P2RX3 P56373 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745633 0.92 MEN1 (0.40) MEN1KMT2AROCK2TP53MAPT
SCHEMBL14741316 0.84 EGLN1 (0.39) MEN1KMT2AROCK2TP53MAPT
SCHEMBL14745792 0.76 GABRG2 (0.44) MEN1KMT2ATP53MAPTLMNA
SCHEMBL14745682 0.76 GABRG2 (0.44) MEN1KMT2ATP53MAPTLMNA
SCHEMBL17495073 0.73 EGLN1 (0.38) MEN1KMT2AHCRTR1HCRTR2TP53
SCHEMBL14745862 0.72 EGLN1 (0.40) MEN1KMT2ATP53MAPTALDH1A1
SCHEMBL14746276 0.72 EGLN1 (0.40) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL14745679 0.72 GABRG2 (0.37) TP53MAPTLMNAALDH1A1TSHR
SCHEMBL14746215 0.72 MEN1 (0.40) MEN1KMT2ALMNAALDH1A1TSHR
SCHEMBL14745810 0.71 MEN1 (0.39) MEN1KMT2ATP53MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 US disclosed
EP-2750678-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033228-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP MEN1 4630/4885KMT2A 4450/4885ROCK2 3820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.